Crucell to Release Q2 2008 Earnings on Tuesday, August 12, 2008
Leiden, The Netherlands (August 5, 2008) - Dutch biopharma company
Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today
announced that it will release its financial results for the second
quarter of 2008 on Tuesday, August 12, 2008 at 07:45 Central European
Time (CET).
At 14:00 Central European Time (CET), Crucell's management will
conduct a conference call, which will also be webcast. To participate
in the conference call, please call one of the following telephone
numbers 10 minutes prior to the event:
+44 203 023 4471 for the UK;
+1 646 843 4608 for the US; and
+3120 794 8426 for the Netherlands
Following a presentation of the results, the lines will be opened for
a question and answer session.
The live audio webcast can be accessed via the homepage of Crucell's
website at www.crucell.com and will be archived and available for
replay following the event.
About Crucell
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a
global biopharma company focused on research, development, production
and marketing of vaccines, proteins and antibodies that prevent and
treat primarily infectious diseases. Its vaccines are sold in public
and private markets worldwide. Crucell's core portfolio includes a
vaccine against hepatitis B, a fully-liquid vaccine against five
important childhood diseases and a virosome-adjuvanted vaccine
against influenza. Crucell also markets travel vaccines, such as the
only oral anti-typhoid vaccine, an oral cholera vaccine and the only
aluminum-free hepatitis A vaccine on the market. The Company has a
broad development pipeline, with several product candidates based on
its unique PER.C6® production technology. The Company licenses its
PER.C6® technology and other technologies to the biopharmaceutical
industry. Important partners and licensees include DSM Biologics,
sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell is
headquartered in Leiden, the Netherlands, with subsidiaries in
Switzerland, Spain, Italy, Sweden, Korea and the US. The Company
employs over a 1000 people. For more information, please visit
www.crucell.com.
Forward-looking statements
This press release contains forward-looking statements that involve
inherent risks and uncertainties. We have identified certain
important factors that may cause actual results to differ materially
from those contained in such forward-looking statements. For
information relating to these factors please refer to our Form 20-F,
as filed with the U.S. Securities and Exchange Commission on May 7,
2008, and the section entitled "Risk Factors". The Company prepares
its financial statements under International Financial Reporting
Standards (IFRS).
For further information please contact:
Crucell N.V.
Oya Yavuz
Director Corporate Communications & Investor Relations
Tel. +31-(0)71-519 7064
ir@crucell.com
www.crucell.com